Overview

Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer

Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
A prospective evaluation of neoadjuvant FOLFIRINOX regimen in patients with non-metastatic pancreas cancer (Baylor University Medical Center and Texas Oncology Experience)
Phase:
N/A
Details
Lead Sponsor:
Baylor Research Institute
Treatments:
Camptothecin
Fluorouracil
Folfirinox
Irinotecan
Leucovorin
Oxaliplatin
Pancreatin
Pancrelipase